DNA microarrays – future in oncology research and therapy
More details
Hide details
Department of Physiological Sciences, Faculty of Veterinary Medicine, University of Life Sciences – SGGW, Warsaw, Poland
Health Centre of the National Polish Bank, Warsaw, Poland
Tomasz Motyl   

Department of Physiological Sciences, Faculty of Veterinary Medicine, University of Life Sciences, Nowoursynowska 159, 02-776 Warsaw, Poland.
J Pre Clin Clin Res. 2008;2(2):91–96
DNA microarrays are a modern and powerful tool for investigating biological processes through the widespread analysis of genes from a particular cell, tissue, or organism. The completion of the human genome project and the development of microarray technologies have opened new opportunities for progress in cancer research. DNA microarrays analysis became a useful tool for the identification of molecular markers, as well as prognostic and diagnostic potential in different human cancers. The medical implications of the microarray technology are described in many publications, most of them as the result of studies on leukemia, lymphoma and breast cancer. There are also initial articles on the use of microarrays in veterinary oncology. Microarray analysis can be categorized into 3 groups of studies: 1) transcriptomic profi le of different tumour types to find characteristic genes for each tumour type, and the genes responsible for malignancy; 2) describing the disease and its clinical outcome; and 3) identifying therapeutic targets and new markers useful in cancer diagnosis and treatment.
Uma RS, Rajkumar T: DNA Microarray and Breast Cancer – A Review. Int J Hum Genet 2007, 7(1), 49-56.
Okamoto OK: DNA microarrays in cancer diagnosis and prognosis. Einstein 2005, 3(1), 31-34.
Macoska JA: The Progressing Clinical Utility of DNA Microarrays. CA Cancer J Clin 2002, 52, 50-59.
Ramaswamy S, Golub TR: DNA Microarrays in Clinical Oncology. J Clin Oncol 2002, 20(7), 1932-1941.
Pusztaj L, Ayers M, Stec J, Hortobagyi GN: Clinical application of cDNA microarrays in oncology. Oncologist 2003, 8, 252-258.
Armstrong SA, Staunton JE, Silverman LB, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ: MLL translocations specify a distinct gene expression profi le that distinguishes a unique leukemia. Nat Genet 2002, 30, 41-47.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diff use large B-cell lymphoma identifi ed by gene expression profi ling. Nature 2002, 403, 503-511.
Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V: Molecular classifi cation of cutaneous malignant melanoma by gene expression profi ling. Nature 2000, 406, 536-540.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeff rey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumors. Nature 2000, 406, 747-752.
Charafe-Jauff ret E, Ginestier C, Monville F, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci Fe F: Gene expression profi ling of breast cell lines identifi es potential new basal markers. Oncogene 2006, 25, 2273-2284.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeff rey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98, 10869- 10874.
Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J, Raff eld M, Yakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrle W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Sauter G: Gene-expression profi les in hereditary breast cancer. N Engl J Med 2001, 344, 539-548.
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68(9), 3108-3114.
Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB: Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profi ling. Cancer Res 2001, 61, 4683-4688.
Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412, 822- 826.
Huang GS, Yao-Ching Hung, Ann Chen, Meng-Yen: Microarray analysis of ovarian cancer Hong Systems, Man and Cybernetics, IEEE International Conference 2005, Vol. 2 (10-12 Oct.): 1036-1041.
Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J, Boshoff C: Predicting biomarkers for ovarian cancer using gene-expression Microarrays. Brit J Cancer 2004, 90, 686-692.
Chao A, Wang TH, Lai CH: Overview of microarray analysis of gene expression and its application to cervical cancer investigation. Taiwan J Obstet Gynecol 2007, 46(4), 363-373.
Chung YM, Kim BG, Park CS, Huh SJ, Kim J, Park JK, Cho SM, Kim BS, Kim JS, Yoo YD, Bae DS: Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer. Int J Cancer 2005, 117, 194-201.
Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC, Kung WH, Huang SL, Chao FY, Wei ML, Lai CH: Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer 2006, 119, 91-98.
Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, Charafe- Jauff ret E, Loriod B, Bachelart L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero JR, Nguyen C, Viens P, Monges G, Birnbaum D, Houlgatte R: Gene expression profi ling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004, 23, 1377-1391.
Koh KH, Rhee H, Kang HJ, Yang E, You KT, Lee H, Min BS, Kim NK, Nam SW, Kim H: Diff erentia gene expression profi le of metastases in paired primary and metastatic colorectal carcinoma. Oncology 2008, 75(1-2), 92-101.
Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, Misek DE, Greenson JK, Kardia SL, Beer DG, Rennert G, Cho KR, Gruber SB, Fearon ER, Hanash S: Organ-Specifi c Molecular Classifi cation of Primary Lung, Colon, and Ovarian Adenocarcinomas Using Gene Expression Profi les. Am J Pathol 2001, 159, 1231-1238.
Kumaraswamy S, Chinnaiyan P, Shankavaram UT, Lu X, Camphausen K, Tofi lon PJ: Radiation-induced gene translation profi les reveal tumor type and cancer-specifi c components. Cancer Res 2008, 68(10), 3819- 3826.
Rao, NAS, van Wolferen ME, van den Ham R, van Leenen D, Groot Koerkamp MJA, Holstege FCP, Mol JA: cDNA mocroarray profi les of canine mammary tumor cell lines reveal deregulated pathways pertaining to their phenotype. (In press) Animal Genetics 2008.
Krol M, Pawłowski KM, Skierski J, Rao NAS, Hellen E, Mol JA, Motyl T: Transcriptomic profi le of two canine mammary cancer cell lines with diff erent proliferative and anti-apoptotic potential. (In press) J Physiol Pharmacol 2008.
Pawłowski KM, Krol M, Majewska A, Badowska-Kozakiewicz A, Mol JA, Malicka E, Motyl T: Comparison of cellular and tissue transcriptomic profi les in canine mammary tumor. (In press) J Physiol Pharmacol 2008.
Jessen BA, Mullins JS, de Peyster A, Stevens GJ: Assessment of Hepatocytes and Liver Slices as in vitro Test Systems to Predict in vivo Gene Expression. Toxicol Sci 2003, 75, 208-222.
Perkins EJ, Xin Guan WB, Ang C, Wolfi nger RD, Chu TM, Meyer SA, Inouye1 LS: Comparison of transcriptional responses in liver tissue and primary hepatocyte cell cultures after exposure to hexahydro-1, 3, 5- trinitro-1, 3, 5-triazine BMC. Bioinformatics 2006, 7 (Suppl 4) 2222.
Ertel A, Verghese A, Byers SW, Ochs M, Tozeren A: Pathway-specifi c diff erences between tumor cell lines and normal and tumor tissue cells. Mol Cancer 2006, 5, 55.
Rao NAS, van Wolferen ME, Bhatti SFM, Krol M, Holstege FC, Mol JA: Gene expression profi les of progestin-induced canine mammary hyperplasia and spontaneous mammary tumors. (In press) J Physiol.